We next validated the therapeutic potential of mitochondrial translation inhibition in another model pair of MYCN-amplified therapy-naive SK-N-BE(1) and drug-resistant SK-N-BE(2)C neuroblastoma cells, the latter being even more sensitive to DOXY (Figs. 2h, S2). Here, MYCN is linked to neuroblastoma.